Published in Retrovirology on February 03, 2005
What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine? Retrovirology (2009) 1.15
Small non-coding RNAs, mammalian cells, and viruses: regulatory interactions? Retrovirology (2007) 1.12
Initiation of hepatitis C virus infection requires the dynamic microtubule network: role of the viral nucleocapsid protein. J Biol Chem (2009) 1.09
Human immunodeficiency virus type 1 subtype C Tat fails to induce intracellular calcium flux and induces reduced tumor necrosis factor production from monocytes. J Virol (2007) 1.07
Transactivation and signaling functions of Tat are not correlated: biological and immunological characterization of HIV-1 subtype-C Tat protein. Retrovirology (2006) 1.05
Activity of the human immunodeficiency virus type 1 cell cycle-dependent internal ribosomal entry site is modulated by IRES trans-acting factors. Nucleic Acids Res (2011) 0.99
Modifications in host cell cytoskeleton structure and function mediated by intracellular HIV-1 Tat protein are greatly dependent on the second coding exon. Nucleic Acids Res (2010) 0.94
HIV-1 Tat contributes to Alzheimer's disease-like pathology in PSAPP mice. Int J Clin Exp Pathol (2009) 0.94
HIV-1 Tat interacts with LIS1 protein. Retrovirology (2005) 0.92
HIV-1 Tat, apoptosis and the mitochondria: a tubulin link? Retrovirology (2005) 0.91
Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine. Retrovirology (2006) 0.90
Modulation of microtubule assembly by the HIV-1 Tat protein is strongly dependent on zinc binding to Tat. Retrovirology (2008) 0.90
HIV-1 Tat inhibits NGF-induced Egr-1 transcriptional activity and consequent p35 expression in neural cells. J Cell Physiol (2008) 0.88
HIV-1 clade B Tat, but not clade C Tat, increases X4 HIV-1 entry into resting but not activated CD4+ T cells. J Biol Chem (2009) 0.85
Inhibition of PP2A by LIS1 increases HIV-1 gene expression. Retrovirology (2006) 0.83
The cross-talk of HIV-1 Tat and methamphetamine in HIV-associated neurocognitive disorders. Front Microbiol (2015) 0.80
A monoclonal antibody directed against a conformational epitope of the HIV-1 trans-activator (Tat) protein neutralizes cross-clade. J Biol Chem (2012) 0.80
Neurodegenerative effects of recombinant HIV-1 Tat(1-86) are associated with inhibition of microtubule formation and oxidative stress-related reductions in microtubule-associated protein-2(a,b). Neurochem Res (2011) 0.80
Modulation of the stability and activities of HIV-1 Tat by its ubiquitination and carboxyl-terminal region. Cell Biosci (2014) 0.76
Quantitative Analysis of the Microtubule Interaction of Rabies Virus P3 Protein: Roles in Immune Evasion and Pathogenesis. Sci Rep (2016) 0.75
HIV-1 Tat Binding to PCAF Bromodomain: Structural Determinants from Computational Methods. Biology (Basel) (2012) 0.75
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 34.97
Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature (1985) 30.62
Microtubule assembly in the absence of added nucleotides. Proc Natl Acad Sci U S A (1973) 18.46
Microtubules as a target for anticancer drugs. Nat Rev Cancer (2004) 13.93
Genetic variability of the AIDS virus: nucleotide sequence analysis of two isolates from African patients. Cell (1986) 9.01
The trans-activator gene of HTLV-III is essential for virus replication. Nature (1986) 8.65
A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem (1997) 6.52
Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med (1995) 6.50
Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature (1995) 4.95
Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature (1990) 4.47
The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med (2000) 4.08
Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science (1995) 3.46
Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell (1999) 3.14
How does HIV cause AIDS? Science (1993) 2.92
Taxol binds to polymerized tubulin in vitro. J Cell Biol (1981) 2.86
Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J Biol Chem (1999) 2.81
HIV-1 Tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state. EMBO J (1995) 2.01
Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci U S A (2001) 2.00
Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc Natl Acad Sci U S A (2002) 1.64
HIV-1 Tat targets microtubules to induce apoptosis, a process promoted by the pro-apoptotic Bcl-2 relative Bim. EMBO J (2002) 1.50
Interpretation of the light scattering from long rods. J Mol Biol (1974) 1.50
A highly defective HIV-1 strain isolated from a healthy Gabonese individual presenting an atypical western blot. AIDS (1989) 1.40
Tat protein of human immunodeficiency virus type 1 represses expression of manganese superoxide dismutase in HeLa cells. Proc Natl Acad Sci U S A (1993) 1.39
Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine. Proc Natl Acad Sci U S A (1999) 1.32
Human immunodeficiency virus type 1 Tat upregulates interleukin-2 secretion in activated T cells. J Virol (1994) 1.29
Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells'. Cancer Res (2000) 1.27
The human immunodeficiency virus type-1 Tat protein upregulates Bcl-2 gene expression in Jurkat T-cell lines and primary peripheral blood mononuclear cells. Blood (1995) 1.21
Reciprocal modulations between p53 and Tat of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1995) 1.21
Expression of human immunodeficiency virus type I tat results in down-regulation of bcl-2 and induction of apoptosis in hematopoietic cells. Oncogene (1996) 1.13
Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells. Cancer Res (2004) 1.13
The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis. J Biol Chem (2004) 1.13
Susceptibility of HIV-1-TAT transfected cells to undergo apoptosis. Biochemical mechanisms. Oncogene (1999) 1.08
Full peptide synthesis, purification, and characterization of six Tat variants. Differences observed between HIV-1 isolates from Africa and other continents. J Biol Chem (1999) 1.03
Caspase-8 activation independent of CD95/CD95-L interaction during paclitaxel-induced apoptosis in human colon cancer cells (HT29-D4). Biochem Pharmacol (2000) 1.01
Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells. FEBS Lett (2002) 1.01
Techniques for the study of microtubule assembly in vitro. Methods Enzymol (1982) 0.94
Mechanism of colchicine binding to tubulin. Tolerance of substituents in ring C' of biphenyl analogues. Biochemistry (1991) 0.93
HIV-1 Tat interacts with LIS1 protein. Retrovirology (2005) 0.92
Apoptosis and apoptosis-associated perturbations of peripheral blood lymphocytes during HIV infection: comparison between AIDS patients and asymptomatic long-term non-progressors. Clin Exp Immunol (2000) 0.92
Low concentrations of vinflunine induce apoptosis in human SK-N-SH neuroblastoma cells through a postmitotic G1 arrest and a mitochondrial pathway. Mol Pharmacol (2004) 0.91
Involvement of microtubules and mitochondria in the antagonism of arsenic trioxide on paclitaxel-induced apoptosis. Biochem Pharmacol (2002) 0.89
Full-length HIV-1 Tat protein necessary for a vaccine. Vaccine (2004) 0.87
Activation of Bcl-2 promoter-directed gene expression by the human immunodeficiency virus type-1 Tat protein. Virology (1999) 0.86
Programmed cell death and AIDS pathogenesis: significance and potential mechanisms. Curr Top Microbiol Immunol (1995) 0.85
First tau repeat domain binding to growing and taxol-stabilized microtubules, and serine 262 residue phosphorylation. FEBS Lett (2002) 0.83
Interaction of tubulin and cellular microtubules with the new antitumor drug MDL 27048. A powerful and reversible microtubule inhibitor. J Biol Chem (1989) 0.79
Tubulin binding of two 1-deaza-7,8-dihydropteridines with different biological properties: enantiomers NSC 613862 (S)-(-) and NSC 613863 (R)-(+). Biochemistry (1993) 0.79
Identification of a candidate therapeutic autophagy-inducing peptide. Nature (2013) 3.76
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol (2007) 3.23
Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J Virol (2005) 2.29
Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J Virol (2007) 2.03
Tubulin is an inherent component of mitochondrial membranes that interacts with the voltage-dependent anion channel. J Biol Chem (2002) 1.80
Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology (2004) 1.56
Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget (2011) 1.54
Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions. Retrovirology (2007) 1.48
Apo-Hsp90 coexists in two open conformational states in solution. Biol Cell (2008) 1.39
Minimal analytical characterization of engineered nanomaterials needed for hazard assessment in biological matrices. Nanotoxicology (2010) 1.38
Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res (2005) 1.34
Protein protein interaction inhibition (2P2I) combining high throughput and virtual screening: Application to the HIV-1 Nef protein. Proc Natl Acad Sci U S A (2007) 1.34
R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models. PLoS One (2010) 1.29
Memo-RhoA-mDia1 signaling controls microtubules, the actin network, and adhesion site formation in migrating cells. J Cell Biol (2008) 1.25
Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol Cancer Ther (2004) 1.24
Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells. Cancer Res (2006) 1.24
Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment. Curr Cancer Drug Targets (2007) 1.23
Binding of ATP to heat shock protein 90: evidence for an ATP-binding site in the C-terminal domain. J Biol Chem (2002) 1.17
Stably expressed APOBEC3F has negligible antiviral activity. J Virol (2010) 1.15
Stathmin and interfacial microtubule inhibitors recognize a naturally curved conformation of tubulin dimers. J Biol Chem (2010) 1.15
What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine? Retrovirology (2009) 1.15
Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells. Cancer Res (2004) 1.13
The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis. J Biol Chem (2004) 1.13
Pharmacological inhibition of LIM kinase stabilizes microtubules and inhibits neoplastic growth. Cancer Res (2012) 1.12
Tubulin proteomics: towards breaking the code. Anal Biochem (2008) 1.10
Microtubule-targeting agents in angiogenesis: where do we stand? Drug Resist Updat (2006) 1.08
Human immunodeficiency virus type 1 subtype C Tat fails to induce intracellular calcium flux and induces reduced tumor necrosis factor production from monocytes. J Virol (2007) 1.07
Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. J Med Chem (2003) 1.04
HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes. Virology (2007) 1.03
Alzheimer disease specific phosphoepitopes of Tau interfere with assembly of tubulin but not binding to microtubules. FASEB J (2008) 1.02
Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells. FEBS Lett (2002) 1.01
ADP ribosylation factor like 2 (Arl2) protein influences microtubule dynamics in breast cancer cells. Exp Cell Res (2006) 1.00
Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variants. J Biol Chem (2002) 1.00
Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41. PLoS One (2012) 0.99
Tau induces ring and microtubule formation from alphabeta-tubulin dimers under nonassembly conditions. Biochemistry (2004) 0.98
Ca2+/calmodulin transfers the membrane-proximal lipid-binding domain of the v-SNARE synaptobrevin from cis to trans bilayers. Proc Natl Acad Sci U S A (2004) 0.97
NMR investigation of the interaction between the neuronal protein tau and the microtubules. Biochemistry (2007) 0.96
Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif. Virology (2007) 0.96
Antiretroviral therapy does not block the secretion of the human immunodeficiency virus tat protein. Infect Disord Drug Targets (2012) 0.92
A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro and in-vivo glioblastoma models. BMC Cancer (2009) 0.92
Epothilone B inhibits migration of glioblastoma cells by inducing microtubule catastrophes and affecting EB1 accumulation at microtubule plus ends. Biochem Pharmacol (2012) 0.92
The C terminus of HIV-1 Tat modulates the extent of CD178-mediated apoptosis of T cells. J Biol Chem (2005) 0.92
Vif counteracts a cyclophilin A-imposed inhibition of simian immunodeficiency viruses in human cells. J Virol (2007) 0.91
Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells. Angiogenesis (2012) 0.91
Low concentrations of vinflunine induce apoptosis in human SK-N-SH neuroblastoma cells through a postmitotic G1 arrest and a mitochondrial pathway. Mol Pharmacol (2004) 0.91
Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine. Retrovirology (2006) 0.90
Modulation of microtubule assembly by the HIV-1 Tat protein is strongly dependent on zinc binding to Tat. Retrovirology (2008) 0.90
Olesoxime prevents microtubule-targeting drug neurotoxicity: selective preservation of EB comets in differentiated neuronal cells. Biochem Pharmacol (2010) 0.90
Differential induction of rat neuronal excitotoxic cell death by human immunodeficiency virus type 1 clade B and C tat proteins. AIDS Res Hum Retroviruses (2010) 0.89
Differential induction of interleukin-10 in monocytes by HIV-1 clade B and clade C Tat proteins. J Biol Chem (2010) 0.89
Involvement of microtubules and mitochondria in the antagonism of arsenic trioxide on paclitaxel-induced apoptosis. Biochem Pharmacol (2002) 0.89
Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis. J Med Primatol (2010) 0.88
Homonuclear 1H NMR and circular dichroism study of the HIV-1 Tat Eli variant. Retrovirology (2008) 0.88
Bcl-2-enhanced efficacy of microtubule-targeting chemotherapy through Bim overexpression: implications for cancer treatment. Neoplasia (2013) 0.88
Antiangiogenic vinflunine affects EB1 localization and microtubule targeting to adhesion sites. Mol Cancer Ther (2008) 0.88
Full-length HIV-1 Tat protein necessary for a vaccine. Vaccine (2004) 0.87
MVL-PLA2, a snake venom phospholipase A2, inhibits angiogenesis through an increase in microtubule dynamics and disorganization of focal adhesions. PLoS One (2010) 0.87
ATIP3, a novel prognostic marker of breast cancer patient survival, limits cancer cell migration and slows metastatic progression by regulating microtubule dynamics. Cancer Res (2013) 0.87
Transcriptional down-regulation of Bcl-2 by vinorelbine: identification of a novel binding site of p53 on Bcl-2 promoter. Biochem Pharmacol (2009) 0.87
Molecular mechanisms of Tau binding to microtubules and its role in microtubule dynamics in live cells. J Cell Sci (2013) 0.87
New insights into the antibacterial mechanism of action of squalamine. J Antimicrob Chemother (2010) 0.86
Tat mutations in an African cohort that do not prevent transactivation but change its immunogenic properties. Vaccine (2007) 0.85
HIV-1 clade B Tat, but not clade C Tat, increases X4 HIV-1 entry into resting but not activated CD4+ T cells. J Biol Chem (2009) 0.85
Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose. Retrovirology (2014) 0.85
Vinflunine, a novel microtubule inhibitor, suppresses calmodulin interaction with the microtubule-associated protein STOP. Biochemistry (2007) 0.84
ROS-mediated EB1 phosphorylation through Akt/GSK3β pathway: implication in cancer cell response to microtubule-targeting agents. Oncotarget (2014) 0.84
Bcl-2 down-regulation and tubulin subtype composition are involved in resistance of ovarian cancer cells to vinflunine. Mol Cancer Ther (2006) 0.83
Suppression of microtubule dynamics by discodermolide by a novel mechanism is associated with mitotic arrest and inhibition of tumor cell proliferation. Mol Cancer Ther (2003) 0.83
First tau repeat domain binding to growing and taxol-stabilized microtubules, and serine 262 residue phosphorylation. FEBS Lett (2002) 0.83